$TENX
TENAX THERAPEUTICS, INC. Stock $tenx

$tenx Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000165495422011073 Filed on August 11, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.377M	$1.337M	$1.541M
YoY Change	-47.83%	5.2%	12.46%
% of Gross Profit
Research & Development	$1.540M	$1.524M	$1.178M
YoY Change	32.51%	119.91%	-94.74%
% of Gross Profit
Depreciation & Amortization	$1.200K	$1.200K	$1.400K
YoY Change	18.81%	20.0%	27.27%
% of Gross Profit
Operating Expenses	$2.917M	$2.862M	$2.719M
YoY Change	-23.27%	45.68%	-88.55%
Operating Profit	$2.917M	$2.862M	$2.719M
YoY Change	-23.27%	45.68%	-88.55%
Interest Expense	$372.00	$1.484K	-$2.590K
YoY Change		341.67%
% of Operating Profit	0.01%	0.05%	-0.1%
Other Income/Expense, Net	$1.320K	$2.360K	$1.551K
YoY Change	-63.74%	-100.95%
Pretax Income	-$2.917M	-$2.861M	-$2.722M
YoY Change	-23.22%	66.63%	-88.54%
Income Tax
% Of Pretax Income
Net Earnings	$2.917M	$2.861M	-$2.722M
YoY Change	-23.22%	66.63%	-88.54%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$110.8K	-$113.5K	-$108.0K
COMMON SHARES
Basic Shares Outstanding	25.21M shares	25.21M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.806M	$7.229M	$2.869M
YoY Change	-54.44%	86.73%	-28.82%
Cash & Equivalents	$3.806M	$7.229M	$2.869M
Short-Term Investments
Other Short-Term Assets	$707.2K	$872.4K	$587.0K
YoY Change	208.61%	149.35%	19.79%
Inventory
Prepaid Expenses	$707.2K	$872.4K	$587.0K
Receivables
Other Receivables
Total Short-Term Assets	$4.514M	$8.102M	$3.456M
YoY Change	-47.41%	219.94%	-23.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.633K	$10.84K	$12.08K
YoY Change	48.45%	86.29%	-59.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$8.435K	$8.435K	$8.435K
YoY Change	0.0%	0.0%	-15.65%
Total Long-Term Assets	$225.4K	$253.9K	$281.9K
YoY Change	-31.35%	-28.05%	604.87%
TOTAL ASSETS
Total Short-Term Assets	$4.514M	$8.102M	$3.456M
Total Long-Term Assets	$225.4K	$253.9K	$281.9K
Total Assets	$4.739M	$8.355M	$3.738M
YoY Change	-46.82%	189.6%	-18.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$265.4K	$919.4K	$1.287M
YoY Change	-65.81%	16.09%	28.71%
Accrued Expenses	$424.4K	$434.5K	$460.5K
YoY Change	-38.05%	13.44%	109.32%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$91.88K	$228.8K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$689.8K	$1.446M	$1.976M
YoY Change	-52.8%	23.05%	38.21%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$95.35K	$125.9K	$155.0K
YoY Change	-54.94%	-47.34%
Total Long-Term Liabilities	$95.35K	$125.9K	$155.0K
YoY Change	-54.94%	-47.34%	416.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$689.8K	$1.446M	$1.976M
Total Long-Term Liabilities	$95.35K	$125.9K	$155.0K
Total Liabilities	$785.2K	$1.572M	$2.131M
YoY Change	-53.07%	11.15%	45.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$287.0M	-$284.1M	-$281.2M
YoY Change	4.25%	4.64%
Common Stock	$2.998K	$2.521K	$2.521K
YoY Change	18.97%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.954M	$6.784M	$1.606M
YoY Change
Total Liabilities & Shareholders Equity	$4.739M	$8.355M	$3.738M
YoY Change	-46.82%	189.6%	-18.03%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	$2.917M	$2.861M	-$2.722M
YoY Change	-23.22%	66.63%	-88.54%
Depreciation, Depletion And Amortization	$1.200K	$1.200K	$1.400K
YoY Change	18.81%	20.0%	27.27%
Cash From Operating Activities	-$3.331M	-$3.431M	-$2.938M
YoY Change	10.24%	85.85%	-8.8%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$6.323K
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Cash From Investing Activities	$0.00	$0.00	-$6.323K
YoY Change	-100.0%	-100.0%	-82.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-91.88K	7.792M	$228.8K
YoY Change	-101.0%	167463.66%	-58.0%
NET CHANGE
Cash From Operating Activities	-3.331M	-3.431M	-$2.938M
Cash From Investing Activities	0.000	0.000	-$6.323K
Cash From Financing Activities	-91.88K	7.792M	$228.8K
Net Change In Cash	-3.423M	4.360M	-$2.715M
YoY Change	-151.22%	-334.58%	0.07%
FREE CASH FLOW
Cash From Operating Activities	-$3.331M	-$3.431M	-$2.938M
Capital Expenditures	$0.00	$0.00	$6.323K
Free Cash Flow	-$3.331M	-$3.431M	-$2.944M
YoY Change	10.3%	86.04%	-8.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	tenx	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-1.60
	tenx	Remaining Lease Term RemainingLeaseTerm	P21Y
	dei	Entity Central Index Key EntityCentralIndexKey	0000034956
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	4818654	shares
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5583922	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	872363	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	105078	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	8101542	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	5689000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	234662	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25206914	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25206914	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25206914	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-34600
	dei	Entity Registrant Name EntityRegistrantName	TENAX THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2593535
	dei	Entity Address Address Line1 EntityAddressAddressLine1	ONE Copley Parkway
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 490
	dei	Entity Address City Or Town EntityAddressCityOrTown	Morrisville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NC
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	27560
	dei	City Area Code CityAreaCode	919
	dei	Local Phone Number LocalPhoneNumber	855-2100
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	TENX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25206914	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7229179	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	287692	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10844	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7108	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8435	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8435	usd
CY2022Q2	us-gaap	Assets Assets	8355483	usd
CY2021Q4	us-gaap	Assets Assets	5992235	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	919384	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	859638	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	434539	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	704340	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	91875	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1445798	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	336	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1563978	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	125883	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	183589	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	125883	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	183589	usd
CY2022Q2	us-gaap	Liabilities Liabilities	1571681	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1747567	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	4818654	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25206914	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	2521	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2521	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	290858023	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	282736332	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-284076742	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-278494185	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	6783802	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	4244668	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8355483	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5992235	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1337427	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1271278	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2878171	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2644738	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1524465	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	693222	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2702360	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23069424	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2861892	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	1964500	usd
	us-gaap	Operating Expenses OperatingExpenses	5580531	usd
	us-gaap	Operating Expenses OperatingExpenses	25714162	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	2861892	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	1964500	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	5580531	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	25714162	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	1484	usd
	us-gaap	Interest Expense InterestExpense	4071	usd
	us-gaap	Interest Expense InterestExpense	949	usd
CY2022Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-2355	usd
CY2021Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-247820	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-2045	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-249955	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	2861021	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	1717016	usd
	us-gaap	Net Income Loss NetIncomeLoss	5582557	usd
	us-gaap	Net Income Loss NetIncomeLoss	25465156	usd
CY2022Q2	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	0	usd
CY2021Q2	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-128	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	0	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	204	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2861021	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1716888	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5582557	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	25465360	usd
CY2022Q2	tenx	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.11
CY2021Q2	tenx	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.10
	tenx	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.22
CY2022Q2	tenx	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	25206914	shares
CY2021Q2	tenx	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	17218103	shares
	tenx	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	25206914	shares
	tenx	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	15874062	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	4625562	usd
CY2021Q1	tenx	Common Stock And Preferred Stock Issued For Asset Acquisition Amount CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount	21582331	usd
CY2021Q1	tenx	Compensation On Options Issued CompensationOnOptionsIssued	91609	usd
CY2021Q1	tenx	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	544651	usd
CY2021Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-332	usd
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-23748140	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	3095681	usd
CY2021Q2	tenx	Common Stock Issued For Convertible Preferred Stock Amount CommonStockIssuedForConvertiblePreferredStockAmount	0	usd
CY2021Q2	tenx	Compensation On Options Issued CompensationOnOptionsIssued	92339	usd
CY2021Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	128	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-1717016	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	1471132	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	4244668	usd
CY2022Q1	tenx	Compensation On Options Issued CompensationOnOptionsIssued	83069	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-2721536	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1606201	usd
CY2022Q2	tenx	Pre Fiunded Warrants And Warrants Sold Net Of Offering Costs PreFiundedWarrantsAndWarrantsSoldNetOfOfferingCosts	7928591	usd
CY2022Q2	tenx	Compensation On Options Issued CompensationOnOptionsIssued	110031	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-2861021	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	6783802	usd
	tenx	Net Loss NetLoss	-5582557	usd
	tenx	Net Loss NetLoss	-25465156	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2588	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2026	usd
	us-gaap	Increase Decrease In Interest And Dividends Receivable IncreaseDecreaseInInterestAndDividendsReceivable	-4071	usd
	us-gaap	Increase Decrease In Interest And Dividends Receivable IncreaseDecreaseInInterestAndDividendsReceivable	-949	usd
	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	53029	usd
	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	53859	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	247233	usd
	tenx	Issuance And Vesting Of Compensatory Stock Options And Warrants IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants	193100	usd
	tenx	Issuance And Vesting Of Compensatory Stock Options And Warrants IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants	183948	usd
	tenx	Issuance Of Common Stock And Preferred Stock For Asset Acquisition IssuanceOfCommonStockAndPreferredStockForAssetAcquisition	0	usd
	tenx	Issuance Of Common Stock And Preferred Stock For Asset Acquisition IssuanceOfCommonStockAndPreferredStockForAssetAcquisition	21582331	usd
	tenx	Amortization Of Premium On Marketable Securities AmortizationOfPremiumOnMarketableSecurities	0	usd
	tenx	Amortization Of Premium On Marketable Securities AmortizationOfPremiumOnMarketableSecurities	6896	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	771355	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	267284	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-210056	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-923295	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-57706	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	6720	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6368886	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5066239	usd
	tenx	Sale Of Marketable Securities SaleOfMarketableSecurities	0	usd
	tenx	Sale Of Marketable Securities SaleOfMarketableSecurities	-290184	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	345540	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6323	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1875	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6323	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-57231	usd
	tenx	Proceeds From Issuance Of Warrants And Pre Funded Warrants Net Of Issuance Costs ProceedsFromIssuanceOfWarrantsAndPreFundedWarrantsNetOfIssuanceCosts	7928591	usd
	tenx	Proceeds From Issuance Of Warrants And Pre Funded Warrants Net Of Issuance Costs ProceedsFromIssuanceOfWarrantsAndPreFundedWarrantsNetOfIssuanceCosts	0	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	364546	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	272671	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	544651	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8020466	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	544651	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1645257	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4578819	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5583922	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6250241	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7229179	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1671422	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	333779	usd
CY2022Q2	tenx	Accumulated Deficit AccumulatedDeficit	-284100000	usd
CY2021Q4	tenx	Accumulated Deficit AccumulatedDeficit	-278500000	usd
	tenx	Net Cash Used In Operating Activities NetCashUsedInOperatingActivities	-6400000	usd
	tenx	Net Cash Used In Operating Activities NetCashUsedInOperatingActivities	-5100000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The preparation of the accompanying unaudited condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted.</p>
	tenx	Liquidity And Capital Resources LiquidityAndCapitalResources	<p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">On June 30, 2022, the Company had cash and cash equivalents of approximately $7.2 million. The Company used $6.4 million of cash for operating activities during the six months ended June 30, 2022 and had stockholders’ equity of $6.8 million, versus $4.2 million on December 31, 2021.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The Company expects to continue to incur expenses related to development of imatinib for PAH, levosimendan for pulmonary hypertension, and other potential indications, as well as identifying and developing other potential product candidates. Based on its resources on June 30, 2022, the Company believes that it has sufficient capital to fund its planned operations through the fourth quarter of calendar year 2022. However, the Company will need substantial additional financing in order to fund its operations beyond such period and thereafter until it can achieve profitability, if ever. The Company depends on its ability to raise additional funds through various potential sources, such as equity and debt financing, or licensing its product candidates to another pharmaceutical company. The Company will continue to fund operations from cash on hand and through sources of capital similar to those previously described. The Company cannot provide assurance that it will be able to secure such additional financing on reasonable terms, or if available, that it will be sufficient to meet its needs.</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">To the extent that the Company raises additional funds by issuing shares of its common stock or other securities convertible or exchangeable for shares of common stock, stockholders will experience dilution, which may be significant. In the event the Company raises additional capital through debt financings, the Company may incur significant interest expense and become subject to restrictive covenants in the related transaction documentation that may affect the manner in which the Company conducts its business. To the extent that the Company raises additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to its technologies or product candidates or grant licenses on terms that may not be favorable to the Company.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The continued spread of COVID-19 globally could adversely affect the Company’s clinical trial operations, including its ability to recruit and retain patients, principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. Further, some patients may be unable to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services, or if the patients become infected with COVID-19 themselves, which would delay the Company’s ability to initiate and/or complete planned clinical and preclinical studies in the future.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Any or all of the foregoing may have a material adverse effect on the Company’s business and financial performance.</p>
CY2022Q2	tenx	Cash And Cash Equivalents CashAndCashEquivalents	7200000	usd
	tenx	Net Cash Used In Operating Activities NetCashUsedInOperatingActivities	-6400000	usd
CY2022Q2	tenx	Total Stockholders Equity TotalStockholdersEquity	6800000	usd
CY2021Q4	tenx	Total Stockholders Equity TotalStockholdersEquity	4200000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	64095	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	129797	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	65702	usd
	us-gaap	Debt Instrument Term DebtInstrumentTerm	P12Y
CY2022Q2	us-gaap	Depreciation Depreciation	1200	usd
CY2021Q2	us-gaap	Depreciation Depreciation	1000	usd
	us-gaap	Depreciation Depreciation	2600	usd
	us-gaap	Depreciation Depreciation	2000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	259594	usd
CY2022Q2	tenx	Less Imputed Interest LessImputedInterest	-20555	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	239039	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	239534	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	113156	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	107192	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	81849	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	597148	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	434539	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	704340	usd
	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	364546	usd
CY2022Q2	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.0324	pure
	tenx	Monthly Installment MonthlyInstallment	46124	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1484	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	4070	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	91875	usd
CY2015Q3	us-gaap	Area Of Land AreaOfLand	5954	sqft
	tenx	Lease Term Period LeaseTermPeriod	P64Y
	us-gaap	Description Of Lessee Leasing Arrangements Operating Leases DescriptionOfLesseeLeasingArrangementsOperatingLeases	The Company has two five-year options to extend the Lease and a one-time option to terminate the Lease 36 months after the commencement of the initial term if no additional space became available. On April 2, 2021, the Company negotiated a three-year extension to the existing lease term
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	125034	usd
	tenx	Percentage Of Annual Increase In Rent PercentageOfAnnualIncreaseInRent	0.025	pure
	tenx	Classification Of Lease Liabilities Tabletextblock ClassificationOfLeaseLiabilitiesTabletextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30, 2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Current portion included in accrued liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">113,156</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">107,192</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Long term lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">125,883</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">183,589</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">239,039</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">290,781</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	113156	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	107192	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	125883	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	183589	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	239039	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	290781	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080	pure
	us-gaap	Lease Cost LeaseCost	62121	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	396	usd
	tenx	Common Stock Acquired CommonStockAcquired	1892905	shares
CY2022Q2	tenx	Series B Convertible Preferred Stock Conversion SeriesBConvertiblePreferredStockConversion	10232	shares
CY2022Q2	tenx	Common Stock For Conversion CommonStockForConversion	10232000	shares
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	1212492	shares
	tenx	Percentage Of Preferred Stock Carries Voting Rights PercentageOfPreferredStockCarriesVotingRights	0.10	pure
	tenx	Fgdf fgdf	881.5 shares of common stock, and (ii) the right to receive up to 118.5 Holdback Shares, to be delivered 24 months after the date of issuance of the Series B Stock, subject to reduction for indemnification claims
	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	3369371	usd
	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1	18212960	usd
	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	21582331	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	0	usd
CY2022Q2	tenx	Accounts Payable Assumed AccountsPayableAssumed	-150000	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	-150000	usd
	tenx	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	21732331	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	21582331	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	tenx	Conversion Price Per Share ConversionPricePerShare	1.93
CY2022Q2	tenx	Conversion Of Preferred Stock Into Common Stock Maximum Ownership Limit Percentage ConversionOfPreferredStockIntoCommonStockMaximumOwnershipLimitPercentage	0.0499	pure
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25206914	shares
CY2022Q2	tenx	Sell And Issue Units SellAndIssueUnits	4773269	shares
CY2021Q3	tenx	Purchase Price Per Unit PurchasePricePerUnit	2.095
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	31524794	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	20928767	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.45
	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	10596027	shares
	tenx	Weighted Average Exercise Price Issued WeightedAverageExercisePriceIssued	0.63
	tenx	Warrants Amended And Restated WarrantsAmendedAndRestated	-9206120	shares
	tenx	Weighted Average Exercise Price Amended And Restared WeightedAverageExercisePriceAmendedAndRestared	1.72
	tenx	Warrants Amended And Restated One WarrantsAmendedAndRestatedOne	9206120	shares
	tenx	Weighted Average Exercise Price Amended And Restared One WeightedAverageExercisePriceAmendedAndRestaredOne	0.63
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	31524794	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.86
CY2020Q1	tenx	Unregistered Warrants To Purchase UnregisteredWarrantsToPurchase	2360313	shares
CY2020Q1	tenx	Exercise Price Per Unit ExercisePricePerUnit	1.04
CY2022Q2	tenx	Reducing Exercise Price ReducingExercisePrice	0.63
	tenx	Shares Available For Grant SharesAvailableForGrant	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Available for </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Grant</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balances, at December 31, 2021</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shares reserved under 2022 Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,100,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shares rolled over from 2016 Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">819,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(571,250</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balances, at June 30, 2022</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,348,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>

Files In Submission

Name	View Source	Status
0001654954-22-011073-index-headers.html	Edgar Link	pending
0001654954-22-011073-index.html	Edgar Link	pending
0001654954-22-011073.txt	Edgar Link	pending
0001654954-22-011073-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tenx-20220630.xsd	Edgar Link	pending
tenx_10q.htm	Edgar Link	pending
tenx_ex311.htm	Edgar Link	pending
tenx_ex312.htm	Edgar Link	pending
tenx_ex321.htm	Edgar Link	pending
tenx_ex322.htm	Edgar Link	pending
tenx-20220630_def.xml	Edgar Link	unprocessable
tenx-20220630_lab.xml	Edgar Link	unprocessable
tenx-20220630_cal.xml	Edgar Link	unprocessable
tenx-20220630_pre.xml	Edgar Link	unprocessable
tenx_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TENX
TENAX THERAPEUTICS, INC. Stock $tenx

2022 Q3 Form 10-Q Financial Statement

#000165495422011073 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TENX TENAX THERAPEUTICS, INC. Stock $tenx

2022 Q3 Form 10-Q Financial Statement

#000165495422011073 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TENX
TENAX THERAPEUTICS, INC. Stock $tenx